Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

Core Insights - Illumina, Inc. has acquired Fluent BioSciences to enhance its capabilities in single-cell research, aligning with its multiomics growth strategy [1] - The acquisition was completed on July 9 and was funded with cash on hand, though financial terms were not disclosed [1] Single-Cell Research Capabilities - Fluent BioSciences has developed a unique single-cell technology that simplifies the analysis process, making it more accessible and cost-effective [2] - The latest product, PIPseq V, can detect a wide range of cell types and is scalable, processing from 100 to 1 million cells [2] Integration and Synergy Benefits - The integration of Fluent's technology with Illumina's sequencing and informatics solutions is expected to provide a comprehensive solution for single-cell multiomic analysis [3] - This combined offering aims to accelerate research discoveries and enhance the company's product portfolio for single-cell analysis [3] Market Prospects - The global single-cell analysis market is valued at $4.34 billion in 2023 and is projected to grow at a CAGR of 18.7% from 2024 to 2030 [4] - Growth drivers include applications in disease diagnosis, drug discovery, and precision medicine, along with advancements in technology that improve detection capabilities [4] Illumina's Position in Cell Sequencing - Illumina is focused on strengthening its position in the gene sequencing market with competitive products and developing sample-to-answer solutions for clinical adoption [5] - The company is also expanding its genomic capabilities in India and aims to drive greater adoption of next-generation sequencing (NGS) technology [6][7] Share Performance - Over the past year, Illumina's shares have decreased by 23.4%, while the industry has seen a decline of 7% [8]